GSK GSK

equity

Price History

1988-06 · DCA start£2.41

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

1988-062026-08 · -17.5%

Worst drawdown: −50%, peaking Mar 1999 and bottoming Apr 2009 — 296 months below the prior high before recovering.

DCA Backtest

Start month

Monthly amount (GBP)

Invested: £42,100
Value today: £73,108
Return: +73.7%
Months invested: 421

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be £73,265 today, so the real (inflation-adjusted) return is -0.2%.

Lump sum instead — £42,100 all at once in Jun 1988: £316,896 (+652.7%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Feb 2026): £649.88 on £700 invested (-7.2%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

	J	F	M	A	M	J	J	A	S	O	N	D
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1988-06: +73.7%

About GSK

GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. (Wikipedia)

It's a listed company categorised under health care.

It rates Medium-High Risk at 2.4/5, meaning real but ordinary risk — the kind most mainstream assets carry, with some factors scoring poorly.

What pushes the score up: earnings quality (5.0/5) and governance (3.0/5).

Scoring well: liquidity at 1.0/5.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-High Risk(2.4/5)100% rated

How these ratings work

Market / Volatility1.7/5 · weight 20%

Annualised volatility (3yr)2/522.0
Max drawdown from ATH2/549.8
Beta vs S&P 5001/50.09

Liquidity1.0/5 · weight 15%

Avg daily $ volume1/5131.1m
Float % of shares outstandingnot yet researched

Leverage / Financial2.0/5 · weight 20%

Debt / equity3/51.1
Interest coverage (EBIT / interest)1/511.8

Earnings Quality5.0/5 · weight 15%

3yr EPS volatility5/5105

Concentration2.0/5 · weight 10%

Largest customer, % of revenuenot yet researched
Geographic revenue concentration2/5majority stable region

Governance3.0/5 · weight 10%

Board independence %not yet researched
Share structurenot yet researched
Litigation / audit history3/5material settled

Sector / Regulatory3.0/5 · weight 10%

Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.